Charles River Laboratories International (CRL) – Investment Analysts’ Recent Ratings Updates

Charles River Laboratories International (NYSE: CRL) has recently received a number of price target changes and ratings updates:

• 10/14/2024 – Charles River Laboratories International is now covered by analysts at Redburn Atlantic. They set a “sell” rating and a $151.00 price target on the stock.
• 10/8/2024 – Charles River Laboratories International was downgraded by analysts at StockNews.com from a “buy” rating to a “hold” rating.
• 10/7/2024 – Charles River Laboratories International was downgraded by analysts at Evercore ISI from an “outperform” rating to an “inline” rating. They now have a $190.00 price target on the stock, down previously from $225.00.
• 10/2/2024 – Charles River Laboratories International was downgraded by analysts at Bank of America Co. from a “buy” rating to a “neutral” rating. They now have a $215.00 price target on the stock, down previously from $250.00.
• 10/1/2024 – Charles River Laboratories International was downgraded by analysts at Citigroup Inc. from a “neutral” rating to a “sell” rating. They now have a $175.00 price target on the stock, down previously from $215.00.
• 9/20/2024 – Charles River Laboratories International had its price target lowered by analysts at Robert W. Baird from $191.00 to $190.00. They now have a “neutral” rating on the stock.
• 8/20/2024 – Charles River Laboratories International was upgraded by analysts at StockNews.com from a “hold” rating to a “buy” rating.

Charles River Laboratories International Stock Up 0.1 %

NYSE:CRL opened at $193.14 on Tuesday. The company has a current ratio of 1.58, a quick ratio of 1.21 and a debt-to-equity ratio of 0.65. The stock has a fifty day simple moving average of $198.14 and a 200-day simple moving average of $215.36. The company has a market cap of $9.95 billion, a price-to-earnings ratio of 22.72, a price-to-earnings-growth ratio of 5.11 and a beta of 1.36. Charles River Laboratories International, Inc. has a twelve month low of $161.65 and a twelve month high of $275.00.

Charles River Laboratories International (NYSE:CRL) last released its quarterly earnings data on Wednesday, August 7th. The medical research company reported $2.80 earnings per share for the quarter, beating the consensus estimate of $2.39 by $0.41. The firm had revenue of $1.03 billion during the quarter, compared to the consensus estimate of $1.03 billion. Charles River Laboratories International had a return on equity of 14.96% and a net margin of 10.83%. Analysts anticipate that Charles River Laboratories International, Inc. will post 10.01 EPS for the current year.

Institutional Trading of Charles River Laboratories International

Several institutional investors and hedge funds have recently made changes to their positions in CRL. Tortoise Investment Management LLC raised its holdings in shares of Charles River Laboratories International by 77.0% in the second quarter. Tortoise Investment Management LLC now owns 131 shares of the medical research company’s stock valued at $27,000 after acquiring an additional 57 shares in the last quarter. Headlands Technologies LLC bought a new stake in shares of Charles River Laboratories International in the first quarter valued at about $41,000. Whittier Trust Co. of Nevada Inc. grew its stake in Charles River Laboratories International by 219.3% in the second quarter. Whittier Trust Co. of Nevada Inc. now owns 281 shares of the medical research company’s stock valued at $58,000 after purchasing an additional 193 shares during the last quarter. Concord Wealth Partners grew its stake in Charles River Laboratories International by 362.5% in the first quarter. Concord Wealth Partners now owns 259 shares of the medical research company’s stock valued at $70,000 after purchasing an additional 203 shares during the last quarter. Finally, Sunbelt Securities Inc. grew its stake in Charles River Laboratories International by 1,072.7% in the first quarter. Sunbelt Securities Inc. now owns 258 shares of the medical research company’s stock valued at $70,000 after purchasing an additional 236 shares during the last quarter. 98.91% of the stock is currently owned by institutional investors.

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).